MARKET WIRETradingView • 1d ago
Niki BioSolutions Launches $1.396 Million ATM Equity Program With H.C. WainwrightTradingView report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
Why NIKI Stock dropped -4.52% Today — RQD Quant Desk Flash
$1.69 -4.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.67
Niki BioSolutions Inc. (NIKI) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $5.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NIKI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NIKI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Niki BioSolutions Inc. (NASDAQ: NIKI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.69 (-4.52% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 486 tracked Industrials issuers, NIKI ranks #393 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NIKI compare to UCAR and RETO in the Industrials sector?
▼
Within the Industrials sector (Industrial Machinery/Components), NIKI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.9%. By comparison, UCAR (U Power Limited (Class A)) holds a E grade (19/100 RQD, P/E N/A, ROIC -18.5%, cap $5.3M) and RETO (ReTo Eco-Solutions Inc. (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $4.2M). Among the 5-stock peer group, NIKI leads on earnings multiple (N/A) while NIKI leads on capital efficiency (-5.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NIKI?
▼
Per NIKI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001734005), Niki BioSolutions Inc. generated $7.9M in revenue (+15.9% YoY), -$1.4M in net income, and -$1.8M in free cash flow against $18.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.67 (-1.00%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-11.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NIKI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY NIKI SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (31% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 25 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$2.63-22.8% Next Q
40
Q2 (-2Q)Grade E$2.03-5.4% Next Q
37
Q3 (-1Q)Grade E$1.92-12% Next Q
35
CurrentGrade E$1.69-9.2% Hist 90D α
32
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NIKI Turnaround Squeeze
While NIKI currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Industrials with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.37) and Max Pain ($1.77) forces dealer call-delta covering toward $18.06.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NIKI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NIKI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NIKI Stock dropped -4.52% Today — RQD Quant Desk Flash
Niki BioSolutions Inc. (NIKI) dropped -4.52% to $1.69, trading at 2% of its 52-week range ($1.7 – $17.2). Stretched risk/reward at current multiples (-6% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.7 – $17.2) with RSI-14 at 25 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.69 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NIKI Headlines & Catalysts
MARKET WIREYahoo Finance • 1d ago
Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter ResearchYahoo Finance report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Niki BioSolutions (Nasdaq:NIKI) - Stock AnalysisSimply Wall St report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
A genetic test tied to Alzheimer’s risk can now use urine, plasma or dried blood spotsStock Titan report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 1d ago
Form 4 Niki BioSolutions: Kira Sheinerman (Director, 10% Owner) For: 22 JulyInvesting.com UK report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session - XORTX Therapeutics (NASDAQ:XRTX), EdesaBenzinga report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com Canada • 2d ago
Niki BioSolutions receives New York approval for expanded APOE test By Investing.comInvesting.com Canada report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 8d ago
Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and UrineNYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research use NEW HAVEN, CT and PRINCETON, NJ, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc
CATALYSTBenzinga • 8d ago
New York State Department Of Health Provides Clinical Laboratory Evaluation Program Test Approval To Niki BioSolutions' DiamiR Biosciences Subsidiary For Its APOE Genotyping TestNiki BioSolutions, Inc. (NASDAQ: NIKI) ("Niki BioSolutions" or the "Company"), a clinical-stage life sciences company focused on developing advanced genomic and biomarker testing solutions, today
MARKET WIREYahoo • 18d ago
Niki BioSolutions’ Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation’s “Rett Research Tool Belt” SeriesCompany’s blood-based microRNA biomarker panel is designed to support monitoring of disease progression and treatment response in Rett syndrome Access the “Rett Research Tool Belt” at https://www.rettsyndrome.org/toolbel
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NIKI)
- ✓Walkthrough of NIKI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NIKI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.88%▼ SUPPORT BREAKDOWN
2026-11-03O $1.96H $1.96L $1.69C $1.69VOL 10.0K
RES: $6.59SUP: $2.39SMA50: $4.37SMA200: $7.63
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NIKI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +15.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on NIKI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NIKI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NIKI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NIKI)
Industrials Rank #393 of 486
⚔️ UCAR vs NIKI Full Matrix →
1. Head-to-Head Industrials Peer Comparison (NIKI vs. UCAR, RETO, XPON, DFLI)
Industry: Industrial Machinery/Components (208 Tracked Issuers)Across 486 tracked Industrials securities in the Roarable RQD universe, Niki BioSolutions Inc. (NIKI) ranks #393 by composite RQD confidence (32/100, grade E) and #461 by equity capitalization ($5.2M). Within this direct 5-issuer industry benchmark cohort, NIKI leads on earnings valuation at N/A trailing P/E, while NIKI leads on capital efficiency and profitability with -5.9% ROIC and — gross margin. XPON currently holds the highest overall quantitative score in the immediate peer group at 33/100 (E) compared with NIKI at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NIKI
ACTIVE
Niki BioSolutions Inc. | E | 32/100 | — | — | -5.9% | -4.52% | $5.2M | Benchmark Subject |
| UCAR U Power Limited (Class A) | E | 19/100 | — | 36.3% | -18.5% | +4.69% | $5.3M | /ucar-vs-niki → |
| RETO ReTo Eco-Solutions Inc. (Class A) | E | 21/100 | — | 35.3% | -35.0% | -6.59% | $4.2M | /reto-vs-niki → |
| XPON Expion Energy Inc. | E | 33/100 | — | 13.9% | -35.0% | +1.96% | $3.6M | /xpon-vs-niki → |
| DFLI Dragonfly Energy Holdings Corp. (NV) | E | 25/100 | — | 26.7% | -35.0% | -4.21% | $3.6M | /dfli-vs-niki → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001734005 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Niki BioSolutions Inc. (NIKI) reported GAAP revenue of $7.9M (+15.9% vs. FY2024 revenue of $6.8M , and +1719.8% cumulative change since FY2023) , GAAP net income of -$1.4M, operating cash flow of -$1.8M, and free cash flow of -$1.8M (-54.4% YoY). On the balance sheet, NIKI closed FY2025 with $18.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $7.9M | -$1.4M | -$1.8M | -$1.8M | $18.7M | — |
| FY2024 (FY) | 2024-12-31 | $6.8M | -$4.3M | -$1.2M | -$1.2M | $16.1M | — |
| FY2023 (FY) | 2023-12-31 | $431.4K | -$2.8M | -$7.7M | -$7.7M | — | — |
3. NIKI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NIKI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Niki BioSolutions Inc. (NASDAQ: NIKI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.69 (-4.52% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 486 tracked Industrials issuers, NIKI ranks #393 in composite RQD confidence.
How does NIKI compare to UCAR and RETO in the Industrials sector?
Within the Industrials sector (Industrial Machinery/Components), NIKI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.9%. By comparison, UCAR (U Power Limited (Class A)) holds a E grade (19/100 RQD, P/E N/A, ROIC -18.5%, cap $5.3M) and RETO (ReTo Eco-Solutions Inc. (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $4.2M). Among the 5-stock peer group, NIKI leads on earnings multiple (N/A) while NIKI leads on capital efficiency (-5.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NIKI?
Per NIKI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001734005), Niki BioSolutions Inc. generated $7.9M in revenue (+15.9% YoY), -$1.4M in net income, and -$1.8M in free cash flow against $18.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NIKI trading relative to its 50-day, 200-day, and 52-week technical levels?
NIKI last traded at $1.69 (-4.52% on volume of 25,520 shares), positioning the stock -61.33% below its 50-day simple moving average ($4.37) and -77.85% below its 200-day simple moving average ($7.63). Across its 52-week range of $1.70 to $17.20, NIKI sits at the 0.0% percentile with a 14-day RSI of 25.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.48 to $1.90).
ROARABLE RATING BRIEF • RQD 32/100 (E)
✓ SEC XBRL & RQD VERIFIED
NIKI — Niki BioSolutions Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Niki BioSolutions Inc. (NIKI) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.69 (-4.52% 1D, market capitalization $5.2M).
- Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -5.9%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Niki BioSolutions Inc. Is a NASDAQ-listed issuer classified in the Industrials sector, Industrial Machinery/Components industry. Per the recent news wire, the company has announced a supply agreement for APOE genotyping with Charter Research, indicating a genetic testing product offering.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Niki BioSolutions Inc. (NIKI) reported $7.9M in annual revenue (up from $6.8M in FY2024, +15.9% YoY) and -$1.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($431.4K revenue, -$2.8M net income) through FY2025, NIKI scaled operating cash flow to -$1.8M and free cash flow to -$1.8M, backed by $18.7M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Industrials with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.70 – $17.20 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream suppliers, downstream customers, and sector correlation analysis are — The only observable cross-reference is that the sector classification (Industrials) does not align with the genetic-testing activity described in the news wire, which a prospective investor should keep in mind when assessing the business and its comparables.
- Key Question #1: Can NIKI sustain or expand its — operating margin and -5.9% ROIC against Industrial Machinery/Components peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $7.9M and free cash flow of -$1.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is NIKI's equity valuation to Industrials capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
NIKI Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Niki BioSolutions Inc. (NIKI) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 1d ago
Niki BioSolutions Launches $1.396 Million ATM Equity Program With H.C. Wainwright TradingView report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research Yahoo Finance report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Niki BioSolutions (Nasdaq:NIKI) - Stock Analysis Simply Wall St report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
A genetic test tied to Alzheimer’s risk can now use urine, plasma or dried blood spots Stock Titan report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 1d ago
Form 4 Niki BioSolutions: Kira Sheinerman (Director, 10% Owner) For: 22 July Investing.com UK report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session - XORTX Therapeutics (NASDAQ:XRTX), Edesa Benzinga report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com Canada • 2d ago
Niki BioSolutions receives New York approval for expanded APOE test By Investing.com Investing.com Canada report covering Niki BioSolutions Inc. (NIKI) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo • 8d ago
Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine NYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research use NEW HAVEN, CT and PRINCETON, NJ, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NIKI Bull vs. Bear Conversation Board — What's Your Call at $1.69?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NIKI 🐻 33% BEARISH CONVICTION
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH
🎯 Target: $2.11 (+19.2%)
📌 Pinned Debate Recent news flow includes a commercial supply agreement for APOE genotyping with Charter Research and $3.5M of reported FY 2025 cash, w
Don't sleep on NIKI's setup in Industrials. Recent news flow includes a commercial supply agreement for APOE genotyping with Charter Research and $3.5M of reported FY 2025 cash, which provides some runway for the company's operations.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (32/100) backs up the fundamental quality.
RetailWhale_TX 🐂 BULL
@ShortSeller_Dan Shorting a 3/20 institutional whale-flow stock at $1.77 is dangerous when funds are rotating into Industrials.
SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH
🎯 Target: $1.47 (-16.9%)
Spot @ $1.77 Reported net losses in every period, negative free cash flow, 0% margins, ROIC of -5.9%, and a Piotroski F-Score of 1/9 point to weak f
Fading this rally in NIKI at $1.77. Reported net losses in every period, negative free cash flow, 0% margins, ROIC of -5.9%, and a Piotroski F-Score of 1/9 point to weak fundamentals while a new ATM equity program raises dilution risk.. With a beta of 1.0 and the stock sitting at $1.77 (52-wk range $1.70–$17.20), the easy multiple expansion is already priced in.